Oracle's stock has fallen over 52% in the past year but is expected to recover strongly, with Mizuho Securities predicting a 121% rise to $320 in the next 12 months. This optimism is driven by accelerating cloud infrastructure growth and disciplined cost management that improved operating margins. Analysts also highlight Oracle's potential gains from cloud computing and AI, with an average 12-month price target of $251.52 and a 'Strong Buy' consensus. Investors should monitor Oracle's capital expenditures, which are not expected to exceed $70 billion in FY27, as a key risk factor.
Following the analyst's optimistic outlook on Oracle's stock recovery, the shares are currently trading at USD 141.12 on Pluang as of Sep 15, 2026 20:51 WIB, down 2.49% for the day. The stock remains well below its 52-week high of USD 328.15 but above the 52-week low of USD 114.99, reflecting ongoing market volatility. Oracle's market capitalization stands at $437.81 billion, with a dividend yield of 1.38%, providing a snapshot of its current valuation and investor returns.
Shares of CoreWeave dropped 16% and its bond yields surged as investors grew concerned about heavy borrowing by tech firms for AI projects. The yield on CoreWeave's 2032 bond hit nearly 15%, signaling increased risk perception. Other tech companies l...
Mizuho reaffirmed its $320 price target and 'Outperform' rating for Oracle stock, highlighting a potential 123.46% upside from the current $143.20 price. The firm remains positive despite regulatory and infrastructure challenges with Oracle's Project...
CoreWeave's stock fell 10% following a spike in its unsecured bond yields to 15%, signaling increased borrowing costs and credit risk concerns. The company finances its AI chip capacity largely through debt secured by the chips and customer contracts...
Oracle Health, a provider of cloud-based health record systems, suffered a data breach compromising personal and medical information, including names, social security numbers, medical records, and payment details. Multiple hospitals across the U.S. w...
The AI market rally is driven by hyperscalers' record capital expenditures, expected to reach nearly $800 billion by FY2026, funded increasingly by debt and equity issuance. This has pushed hyperscalers' liabilities above $4 trillion, raising financi...
